US-based Rgenta Therapeutics bags $52m led by AstraZeneca-CICC Capital fund

US-based Rgenta Therapeutics bags $52m led by AstraZeneca-CICC Capital fund

Photo by National Cancer Institute on Unsplash

Massachusetts-based biotechnology firm Rgenta Therapeutics has snagged $52 million in a Series A round led by a fund set up by AstraZeneca and CICC Capital, according to a company announcement on Tuesday.